nach oben

Diabetologia

Erschienen in:

01.01.2006 | Article

The in vivo effects of the Pro12Ala PPARγ2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank

verfasst von: G. D. Tan, M. J. Neville, E. Liverani, S. M. Humphreys, J. M. Currie, L. Dennis, B. A. Fielding, F. Karpe

Erschienen in: Diabetologia | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

To investigate the phenotypic effects of common polymorphisms on adipose tissue metabolism and cardiovascular risk factors, we set out to establish a biobank with the unique feature of allowing a prospective recruit-by-genotype approach. The first use of this biobank investigates the effects of the peroxisome proliferator-activated receptor (PPAR) Pro12Ala polymorphism on integrative tissue-specific physiology. We hypothesised that Ala12 allele carriers demonstrate greater adipose tissue metabolic flexibility and insulin sensitivity.

Materials and methods

From a comprehensive population register, subjects were recruited into a biobank, which was genotyped for the Pro12Ala polymorphism. Twelve healthy male Ala12 carriers and 12 matched Pro12 homozygotes underwent detailed physiological phenotyping using stable isotope techniques, and measurements of blood flow and arteriovenous differences in adipose tissue and muscle in response to a mixed meal containing [1,1,1-¹³C]tripalmitin.

Results

Of 6,148 invited subjects, 1,072 were suitable for inclusion in the biobank. Among Pro12 homozygotes, insulin sensitivity correlated with HDL-cholesterol concentrations, and inversely correlated with blood pressure, apolipoprotein B, triglyceride and total cholesterol concentrations. Ala12 carriers showed no such correlations. In the meal study, Ala12 carriers had lower plasma NEFA concentrations, higher adipose tissue and muscle blood flow, and greater insulin-mediated postprandial hormone-sensitive lipase suppression along with greater insulin sensitivity than Pro12 homozygotes.

Conclusions/interpretation

This study shows that a recruit-by-genotype approach is feasible and describes the biobank’s first application, providing tissue-specific physiological findings consistent with the epidemiological observation that the PPAR Ala12 allele protects against the development of type 2 diabetes.

Kersten S, Desvergne B, Wahli W (2000) Roles of PPARs in health and disease. Nature 405:421–424PubMedCrossRef

Yen CJ, Beamer BA, Negri C et al (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241:270–274PubMedCrossRef

Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMedCrossRef

Ardlie KG, Lunetta KL, Seielstad M (2002) Testing for population subdivision and association in four case-control studies. Am J Hum Genet 71:304–311PubMedCrossRef

Deeb SS, Fajas L, Nemoto M et al (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287PubMedCrossRef

Ek J, Andersen G, Urhammer SA et al (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. Diabetologia 44:1170–1176PubMedCrossRef

Koch M, Rett K, Maerker E et al (1999) The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 42:758–762PubMedCrossRef

Hara K, Okada T, Tobe K et al (2000) The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271:212–216PubMedCrossRef

Buzzetti R, Petrone A, Ribaudo MC et al (2004) The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity. Eur J Hum Genet 12:1050–1054PubMedCrossRef

10.

Masugi J, Tamori Y, Mori H, Koike T, Kasuga M (2000) Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 268:178–182PubMedCrossRef

11.

Masud S, Ye S (2003) Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 40:773–780PubMedCrossRef

12.

Tan GD, Fielding BA, Currie JM et al (2005) The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:83–95PubMedCrossRef

13.

Sarkkinen E, Korhonen M, Erkkila A, Ebeling T, Uusitupa M (1998) Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. Am J Clin Nutr 68:1215–1222PubMed

14.

Lundahl B, Hamsten A, Karpe F (2002) Postprandial plasma ApoB-48 levels are influenced by a polymorphism in the promoter of the microsomal triglyceride transfer protein gene. Arterioscler Thromb Vasc Biol 22:289–293PubMedCrossRef

15.

Auboeuf D, Rieusset J, Fajas L et al (1997) Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46:1319–1327PubMedCrossRef

16.

Guo Z, Hensrud DD, Johnson CM, Jensen MD (1999) Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 48:1586–1592PubMedCrossRef

17.

Office for National Statistics. http://www.oxfordshire.gov.uk/index/living/facts/population_statistics/midyear-population.htm, Accessed 6 January 2005

18.

Welsh K, Bunce M (1999) Molecular typing for the MHC with PCR-SSP. Rev Immunogenet 1:157–176PubMed

19.

Frayn KN, Coppack SW (2001) Assessment of white adipose tissue metabolism by measurement of arteriovenous differences. Methods Mol Biol 155:269–279PubMed

20.

Frayn KN, Coppack SW, Humphreys SM, Whyte PL (1989) Metabolic characteristics of human adipose tissue in vivo. Clin Sci (Lond) 76:509–516

21.

Evans K, Burdge GC, Wootton SA, Clark ML, Frayn KN (2002) Regulation of dietary fatty acid entrapment in subcutaneous adipose tissue and skeletal muscle. Diabetes 51:2684–2690PubMedCrossRef

22.

Larsen OA, Lassen NA, Quaade F (1966) Blood flow through human adipose tissue determined with radioactive xenon. Acta Physiol Scand 66:337–345PubMedCrossRef

23.

Rådegran G (1999) Limb and skeletal muscle blood flow measurements at rest and during exercise in human subjects. Proc Nutr Soc 58:887–898PubMedCrossRef

24.

Williams DR, Wareham NJ, Brown DC et al (1995) Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabet Med 12:30–35PubMedCrossRef

25.

Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E (1995) A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 38:1213–1217PubMedCrossRef

26.

Charles MA, Eschwege E, Thibult N et al (1997) The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 40:1101–1106PubMedCrossRef

27.

Pankow JS, Duncan BB, Schmidt MI et al (2004) Fasting plasma free fatty acids and risk of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes Care 27:77–82PubMedCrossRef

28.

Stumvoll M, Wahl HG, Loblein K et al (2001) Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 50:876–881PubMedCrossRef

29.

Temelkova-Kurktschiev T, Hanefeld M, Chinetti G et al (2004) Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab 89:4238–4242PubMedCrossRef

30.

Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LK, Frayn KN (2002) Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 51:2467–2473PubMedCrossRef

31.

Avena R, Mitchell ME, Nylen ES, Curry KM, Sidawy AN (1998) Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 28:1024–1031PubMedCrossRef

32.

Murakami T, Mizuno S, Ohsato K et al (1999) Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol 84:92–94, A8PubMedCrossRef

33.

Sidhu JS, Cowan D, Kaski JC (2004) Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 94:151–156PubMedCrossRef

34.

Arima S, Kohagura K, Takeuchi K et al (2002) Biphasic vasodilator action of troglitazone on the renal microcirculation. J Am Soc Nephrol 13:342–349PubMed

35.

Song J, Walsh MF, Igwe R et al (1997) Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes 46:659–664PubMedCrossRef

36.

Peuler JD, Warfield RK, Phelps LE (2004) Attenuation by 4–aminopyridine of delayed vasorelaxation by troglitazone. Metabolism 53:147–152PubMedCrossRef

37.

Clark MG, Colquhoun EQ, Rattigan S et al (1995) Vascular and endocrine control of muscle metabolism. Am J Physiol 268:E797–E812PubMed

38.

Baron AD, Clark MG (1997) Role of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr 17:487–499PubMedCrossRef

39.

Gonzalez Sanchez JL, Serrano Rios M, Fernandez Perez C, Laakso M, Martinez Larrad MT (2002) Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 147:495–501PubMedCrossRef

40.

Kim KS, Choi SM, Shin SU, Yang HS, Yoon Y (2004) Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. Metabolism 53:1538–1543PubMedCrossRef

41.

Auwerx J (1999) PPARgamma, the ultimate thrifty gene. Diabetologia 42:1033–1049PubMedCrossRef

42.

Storlien L, Oakes ND, Kelley DE (2004) Metabolic flexibility. Proc Nutr Soc 63:363–368PubMedCrossRef

43.

Kelley DE (2002) Skeletal muscle triglycerides: an aspect of regional adiposity and insulin resistance. Ann N Y Acad Sci 967:135–145PubMedCrossRef

44.

Yamamoto Y, Hirose H, Miyashita K et al (2002) PPAR(gamma)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism 51:1407–1409PubMedCrossRef

45.

Takata N, Awata T, Inukai K et al (2004) Pro12Ala substitution in peroxisome proliferator-activated receptor gamma 2 is associated with low adiponectin concentrations in young Japanese men. Metabolism 53:1548–1551PubMedCrossRef

46.

Thamer C, Machicao F, Fritsche A, Stumvoll M, Häring H (2003) No influence of the PPARgamma2 Pro12Ala genotype on serum adiponectin concentrations in healthy Europeans. Metabolism 52:798; author reply 798–799PubMedCrossRef

Titel: The in vivo effects of the Pro12Ala PPARγ2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank
verfasst von: G. D. Tan
M. J. Neville
E. Liverani
S. M. Humphreys
J. M. Currie
L. Dennis
B. A. Fielding
F. Karpe
Publikationsdatum: 01.01.2006
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 1/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-005-0044-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2006

Diabetes mellitus and impaired fasting glucose in Alaska Eskimos: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study

Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis

Visual acuity and perimetry as measures of visual function in diabetic macular oedema

Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005

To: Mathieu C, Gysemans C, Giulietti A, Bouillon R (2005) Vitamin D and diabetes. Diabetologia 48:1247–1257